Introduction: Several preparative regimens are used in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients prior to autologous hematopoietic stem cell transplant (HSCT). These include CBV (cylophosphamide, etoposide and carmustine), BEAM (carmustine, etoposide, cytarabine and melphalan) or TBI based regimens. This study retrospectively compares the toxicities of CBV vs BEAM in lymphoma post-HSCT in our institution. Methods: We retrospectively reviewed the charts of 77 lymphoma patients who underwent autologous HSCT between 1999 and 2010 . 35 patients received CBV between 1999 and 2005 and 42 patients received BEAM between 1999 and 2010 (12 HL and 30 NHL) . CBV consisted of cyclophosphamide 7200 mg/m 2 , etoposide 1600 mg/m 2 , and carmustine 300 mg/m 2 . BEAM consisted of carmustine 300 mg/m 2 , etoposide 1600 mg/ m 2 , cytarabine 1600 mg/m 2 , and melphalan 140 mg/m 2 . Lung toxicity was defined as a 15% drop in adjusted DLCO (carbon monoxide diffusing capacity) on pulmonary function test (PFT) or respiratory symptoms requiring steroids within six weeks post-HSCT. Clinically significant lung toxicity was defined as respiratory symptoms requiring steroids or leading to death. Results: Lung toxicity occurred in 10/42 (23.8%) of BEAM and 13/35 (37.1%) of CBV patients (p 5 0.203). However, clinically significant lung toxicity occurred only in 3/42 (7.1%) of BEAM (one of which was lethal) and only in 1/35 (2.9%) of CBV patients (p 5 0.621). All 4 clinically significant lung toxicities occurred in HL. Cardiac toxicities were comparable (11.9% after BEAM vs 8.6% after CBV; p 5 0.722). Time to engraftment defined as neutrophil . 500 (12.9 days after CBV vs 11.3 days after BEAM; p 5 0.031), diarrhea (65.7% after CBV vs 31.0% after BEAM; p 5 0.002) and infections requiring intravenous antibiotics (60.0% after CBV vs 14.3% after BEAM; p \ 0.001) were higher after CBV. Severe mucositis requiring parenteral nutrition was comparable (21.4% after BEAM and 14.3 after CBV p 5 0.418). Conclusion: HL patients, especially those who received BEAM, appear to be at higher risk of clinically significant lung toxicity compared to NHL patients. Prior bleomycin may have contributed to this. Most patients who had a 15% decline in DLCO post HSCT did not experience clinically significant lung toxicity. Therefore, the value of post HSCT PFT is unclear and close monitoring of high risk patients for symptoms is warranted. Finally, the time to engraftment and other toxicities favored BEAM. Common G-CSF regimens have doses ranging from 5-16 mcg/kg/ d starting one to several days after chemotherapy until a predetermined variable is reached to initiate peripheral blood stem cell collection. Patients and Methods: We performed a retrospective analysis of stem cell collection with G-CSF after salvage RICE for consecutive patients with relapsed/refractory lymphoma at our center. Our earlier practice was augmenting stem cell mobilization with 16 mcg/kg/ d G-CSF from Day 1 to final day of collection to achieve WBC . 10,000/mm 3 prior to initiating stem collection (Standard dose group). We observed difficulties in terms of adequacy and timing of collection with this method. We modified the regimen to G-CSF at 5 mcg/kg/ d from Day 1 to 7, followed by dose escalation to 16 mcg/kg/d on Day 8 until final day of collection, and a planned peripheral blood stem collection beginning Day 12 (Dose escalation group). Results: Standard dose group: Three patients (2 DLBCL, 1 Hodgkin's lymphoma) received salvage RICE for 2 to 3 cycles. Peripheral blood stem cell collection resulted in CD341 yields of only 0.3 to 3.0 x10 6 per kg in 5 to 6 apheresis sessions initiated between day 11 and day 16. Dose escalation group: Four patients (2 DLBCL, 1 T cell rich B cell lymphoma, 1 Hodgkin's lymphoma) received salvage RICE for 2 to 4 cycles. Peripheral blood stem cell collection resulted in more than sufficient CD341 yields (all . 3x10 6 per kg, range 3.80 to 7.10 x10 6 ) in only 1 to 3 apheresis sessions initiated on day 12. Conclusion: A timed escalation to high dose G-CSF on day 8 salvage RICE chemotherapy for relapsed/refractory lymphoma resulted in superior CD341 cells for collection with fewer apheresis requirements and a predictable apheresis start day.
OPTIMIZING THE EFFICACY OF PLERIXAFOR AS A SALVAGE OPTION IN POOR MOBILIZERS FOLLOWING CHEMOTHERAPY PLUS G-CSF MOBILIZATION
Kochuparambil, S.T. 1 , Mebel, E.R. 3 , DeRemer, D.L. 2 , Jillella, A.P. 1 , Awan, F.T. 1 1 Medical College of Georgia, Augusta, GA; 2 Medical College of Georgia, Augusta, GA; 3 University of Pittsburgh Medical Center, Pittsburgh, PA Introduction: Recent data of the combination of G-CSF (G) with Plerixafor (P) has established its efficacy in stem cell mobilization for autologous transplants. However, there is limited data about the utility of plerixafor in patients who are being mobilized with chemotherapy and G. Methods: In this study we describe our experience with the use of plerixafor as a salvage option in 12 patients (6 Non-Hodgkin Lymphoma, 3 Multiple Myeloma, 2 Hodgkin Lymphoma, 1 Ewings Sarcoma) who fail to optimally mobilize CD34 1 cells (\ 10 CD341 cells/ul at neutrophil recovery) after G. Patients received Cyclophosphamide (CY) (3-4 g/m 2 ) followed by G (10 mcg/kg) from D1 to D10. Data was collected on mobilization and transplant outcomes and analyzed utilizing SPSS version 13.0. Results: The median age was 60 years (range 18-76). 75% were males. Patients had received a median of 2 lines of therapy (range 1-3) prior to stem cell mobilization. Following failure to mobilize with G post CY, at neutrophil recovery patients received a median of 2.5 doses of P (range 1-8). The average number of apheresis sessions was 4.2 and the total number of CD341 stem cells collected was 4.0x10 6 /kg. Utilizing a cut-off of 2x10 6 CD341/kg, one patient who received P had an unsuccessful harvest. Three NHL patients required . 4 doses of P, but all eventually collected . 2 Â 10 6 CD341 S208 Poster Session I cells/kg. The mean peripheral CD34 count prior to the use of P was 3.3/ul, and increased to 8.8/ul after its use. Conclusion: Our limited single-center outcomes data suggests that the addition of P as a salvage agent may improve mobilization outcomes in poor mobilizers. Further evaluation is needed to combine P with CY1G in terms of optimal timing and dosing of chemotherapy utilized. Introduction: Successful transplantation of cryopreserved hematopoietic stem cells can be regularly achieved provided sufficient numbers of cells are administered. The duration of hematopoietic stem cell viability is unclear. Evidence of autologous repopulation has been seen at 14 years after bone marrow transplant and 12 years after peripheral stem cell transplant. We report a successful autologus transplantation 21 y after cryopreservation.
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Case: The patient is 43 year old man found to have follicular lymphoma with bone marrow involvement in 1989 at age 22. He achieved complete remission after treatment with two cycles of Chorambucil. Bone marrow (BM) procurement and cryopreservation was performed at that time for possible subsequent infusion. The procured BM consisted of a total cell count of 1.21 Â 10 8 cells/per kg body weight with a total volume of 354 ml. Equal parts of 20% DMSO were combined with marrow to a final concentration of 10% DMSO. The BM was stored in the liquid phase of nitrogen until date of infusion 21 years later. Our patient relapsed in 1996, and underwent treatment in 2006 with six cycles of Fludarabine and Rituximab, achieving a complete remission. He continued Rituximab maintenance and then developped pancytopenia. Work-up confirmed MDS with 5q-and t(6q21;17p13) in 20/20 cells by karyotype analysis. Assessment of previously cryopreserved marrow was undertaken showing no evidence of cytogenetic or histological changes. The patient was prepared with Busulfan IV at 0.8/kg q 6 hours Â 4 days and Cyclophosphamide 60mg/kg IV Â 2 days. The BM was infused and samples from the infused marrow showed 65-75% viability by Tryptan blue assay. White cell engraftment occurred on day 17 and platelet reached 20,000/uL by day 30.
Follow-up 2 months post transplant revealed WBC of 2.6 x10 3 /uL with ANC 1.5Â10 3 /uL, Hgb 9.8 gr/dl and platelets of 43,000/uL. FISH analysis for 5q performed showed 85/200 cells positive for 5q-. BM biopsy confirmed dysplastic features consistent with his pre-transplant BM.
Our case illustrates that even in the setting of marginal numbers of infused marrow components and after prolonged cryopreservation, repopulation can readily occur. To our knowledge, this is the oldest successful cryopreserved autologous bone transplant at 21 years post preservation. As novel uses of stem cells advance, optimal storage of various cellular components is necessary. This should be further investigated on a larger scale in the future. We theorized that in patients with persistent or relapsed cancer following alloHSCT, tumor would be a source of tumor-reactive donor T lymphocytes that could be expanded ex vivo to provide a potent T cell therapy. We recently reported our initial clinical results demonstrating feasibility, safety and biologic activity of this approach in patients with refractory B cell tumor relapse after al-loHSCT (ASH 2010). We report here the characterization of the initial tumor infiltrate as compared to circulating T cell populations, and as compared to expanded products from tumor and blood. We determined that tumor-infiltrating donor T cells (confirmed by chimerism assays) differed from peripheral donor T cell populations in individual patients in terms of T cell frequency, na€ ıve/memory phenotype, ratio of CD4:CD8 cells and frequencies of effector and regulatory T cell populations. Following a-CD3/ CD28 antibody-coated bead expansion with low dose IL-2, PCR-based chimerism assessment of products demonstrated that the costimulated lymphocytes were of donor origin; by flow, products were greater than 95% CD31 T cells. CD41 T cells usually predominated, but there was significant patient variation in expansions from both tumor infiltrates and blood. Both expanded tumor and blood products demonstrated increased expression of markers of activation and effector function (CD4: CD40L; CD8: CD137, perforin, NKG2D). The proportion of FoxP31 Treg cells declined and IFN-producing TBet1 Th1/Tc1 effectors became the dominant T cell population. While the percentage of cells expressing CD27 and CD28 declined proportionate to the duration of culture, their expression was retained in a significant proportion of cells after our typical 12-day culture. Our findings support the hypothesis that, after allotransplant, donor lymphocytes can be identified in residual/progressing tumor, and appear to be distinct from circulating T cell populations. Furthermore, these tumor-infiltrating T cells can be effectively expanded, even from minor populations, to become T-Bet1 T effectors, plausibly circumventing a mechanism of GVL resistance. Costimulated tumor-derived donor lymphocytes may be a therapeutic option for patients without a source of, or who have not responded to, donor lymphocyte infusion for disease progression after alloHSCT. Relapse remains a significant problem following allogeneic stem cell transplantation (SCT) for AML. Adoptive transfer of leukemiaspecific cytotoxic T lymphocytes (CTL), such as PR1-specific CTL, might be used to treat persistent leukemia after SCT by enhancing graft versus leukemia (GVL) while minimizing graft versus host disease (GVHD). A limitation of this approach is the limited persistence of adoptively transferred T cells in the recipient, due in part to the lengthy ex vivo expansion of low frequency cells necessary to obtain a sufficient cell number. We chose to study PR1-CTL derived from umbilical cord blood (UCB) based on our observation that UCB PR1-CTL are increased 100-to 1,000-fold compared to adult peripheral blood (PB), suggesting UCB might be a rich source of PR1-CTL. Because UCB is associated with a decreased risk of GVHD, in part because of the predominance of naive T cells, it may also be a preferred platform to transfer GVL with minimal risk of GVHD. We found the frequency of PR1-CTL in UCB to be 0.007 to 0.345% (mean 0.117%; n 5 57) of CD81 cells compared with a frequency of\0.001% in healthy adult PB. Therefore, we hypothesized that a sufficient number of PR1-CTL from UCB could be obtained by PR1/HLA-A2 tetramer-based cell sorting and infused without further expansion to mediate GVL. To test this, CD81 T cells from HLA-A21 UCB units were first enriched via whole blood negative immunodensity separation. Enriched cells were sorted (. 98% purity) into PR1-CTL and PR1-CTL-depleted CD81 cells (PDC) and briefly activated ex vivo for 48 hours with soluble anti-CD3/anti-CD28 1 IL-2. After 48 hours, PR1-CTL specifically lysed PR1-pulsed T2 cells although 95% of PR1-CTL and PDC retained a CCR71CD45RA1 naive phenotype. Next, 1 Â 10 4 cells were infused into NOD/SCID mice engrafted for 7 days with 2-4 Â 10 6 human AML blasts. Three separate experiments were performed. Two
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